OTCM
PXXLF
Market cap12mUSD
Nov 03, Last price
0.25
Name
Poxel SA
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.22%
Rev. gr., 5y
-51.60%
Revenues
7m
+234.98%
Net income
-18m
L-47.83%
CFO
-18m
L+25.95%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Poxel S.A., a biopharmaceutical firm in the clinical stage, is dedicated to creating innovative treatments for a range of metabolic disorders, including type 2 diabetes and various liver ailments. Its flagship product, Imeglimin, is an oral drug candidate that has successfully completed Phase III clinical trials in Japan. This promising medication is also undergoing Phase III trials in the United States and Europe for the management of type 2 diabetes. Imeglimin works by enhancing pancreatic beta cell function and mitigating insulin resistance, thereby reducing key cardiovascular and metabolic risk factors such as elevated blood lipid levels and excessive body weight. Additionally, Poxel is advancing PXL770, an activator of the adenosine monophosphate-activated protein kinase (AMPK) enzyme. This compound is currently in a Phase 2a clinical trial, targeting chronic metabolic conditions, notably liver diseases like non-alcoholic steatohepatitis (NASH). The company further expands its therapeutic portfolio through strategic licensing agreements. With Enyo Pharma S.A.S., Poxel is developing PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist, which is presently in a Phase II study for treating both hepatitis B and NASH. Another collaboration, with DeuteRx LLC, involves PXL065, a mitochondrial pyruvate carrier inhibitor, now in a Phase I clinical trial for the treatment of NASH. Established in 2009, Poxel S.A. maintains its headquarters in Lyon, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||